A subscription to JoVE is required to view this content. Sign in or start your free trial.
Human intestinal organoids must be innervated to better recapitulate the structure and function of the native human intestine. Here, we present one method for incorporating an enteric nervous system into these constructs.
The complexity of intestinal cytoarchitecture and function poses significant challenges for the creation of the bioengineered small intestine. Techniques for generating human intestinal organoids (HIOs) resembling human small intestine have been previously reported. HIOs contain epithelium and mesenchyme but lack other critical components of functional intestine such as the enteric nervous system (ENS), immune cells, vasculature, and microbiome. Two independent research groups have published distinct methods to innervate HIOs with an ENS. Here we discuss a unique method of incorporating the ENS into an HIO-derived bioengineered small intestine, which utilizes components of these prior reports to optimize progenitor cell identity as well as developmental timing.
Human pluripotent stem cells (hPSCs) are differentiated to independently generate HIOs and enteric neural crest cells (ENCCs) by temporal regulation of differentiation markers over a period of several days per published protocols. Once HIOs reach the mid-hindgut spheroid stage (approximately day 8), day 15-21 ENCC spheroids are dissociated, co-cultured with HIOs, and suspended within clear three-dimensional (3D) basement membrane matrix droplets. HIO + ENCC co-cultures are maintained in vitro for 28-40 days before transplantation into >9-week-old immunodeficient mice for further development and maturation. Transplanted HIOs (tHIOs) with ENS can be harvested 4-20 weeks later. This method integrates elements from two previously published techniques by utilizing ENCCs generated from hPSCs and co-culturing them with HIOs at an early stage of development to maximize exposure to early developmental cues that likely contribute to the formation of a more mature intestinal morphology.
The human small intestine is a complex, multilayered organ that carries out numerous essential functions such as digestion, nutrient absorption, fluid regulation, immune barrier function, and motility. Numerous clinical diseases, such as short bowel syndrome, enteropathies, or motility disorders, are characterized by critical reduction of intestinal mass or disruptions of normal physiology leading to significant morbidity and mortality1,2,3,4. Current treatment options often include surgery to remove the dysfunctional intestine at the cost of decreased intestinal length and, thereby, the functional capacity of the remaining bowel5. There is a need for regenerative therapies that are additive in nature, increasing functional gut capacity and restoring intestinal function in ways current therapeutic paradigms are unable to achieve.
Bioengineered small intestine is a promising solution to these challenges. Human intestinal organoids (HIOs) derived from human pluripotent stem cells (hPSCs) are one starting material for the bioengineered small intestine. In 2011, Spence et al. first reported the successful creation of modern HIOs from hPSC lines, including both H1 and H9 human embryonic stem cell (hESC) and multiple human induced pluripotent stem cell (hiPSC) lines6,7. Their protocol included a carefully timed series of incubations with specific growth factors to mimic human fetal intestinal development. Activin A, a TGFΞ² signaling molecule, drives hPSC differentiation towards endodermal fate followed by directed posterior patterning with Wnt/FGF. Under these conditions, hPSCs self-organize to form gut spheroids containing polarized epithelium and mesenchyme. 3D culture within a basement membrane matrix allows for additional development resulting in organoids with an internal lumen, villus-like involutions of epithelium, and self-regenerating progenitor cell niches within crypt-like structures.
While HIOs generated using this original 2011 protocol structurally resemble native intestine, they lack the capacity to generate the neurons or glia of the enteric nervous system (ENS). In 2017, two major papers described similar but distinct methods of innervating HIOs. ENS progenitors (enteric neural crest cells, ENCCs) can be derived from hPSCs. In culture, ENCCs form 3D neurospheres, which can differentiate into enteric neurons and glia under appropriate conditions. Workman and Mahe et al. modified an existing protocol to derive ENCCs from hPSCs and treated them with FGF-enriched media followed by retinoic acid for 2 days for posteriorization and promotion of vagal fate8,9. Day 6 neurospheres were incubated for another 4 days without RA, and then migrated cells were collected after enzymatic detachment. Approximately 20,000-50,000 ENCCs were aggregated with early mid-hindgut spheroids and these ENCC-seeded gut spheroids were grown in vitro in a clear 3D basement membrane matrix for 28 days until in vivo engraftment into the kidney capsule of immunodeficient mice for 6-10 weeks. The resulting HIO + ENS demonstrated significant maturation of epithelial and mesenchymal components as well as neuroglial structures similar to ganglia, albeit with lower cell body density than native intestine, absence of certain clinically relevant neuronal subtypes (i.e., CHAT-positive neurons in HIO + ENS after transplantation), and overall fetal-like characteristics.
The same year, Schlieve et al. published an alternative method involving a mixture of 40-60 intact, day 15 ENCC neurospheres with more mature HIOs at the time of in vivo transplantation into the omentum of immunodeficient mice for 3 months without prior in vitro co-culture10. Their constructs, called ENCC-HIO-TESI (tissue-engineered small intestine), appeared to contain a more mature ENS phenotype than that of Workman and Mahe's HIO + ENS with greater neuronal subtype diversity and neuroepithelial synaptic connections not seen in HIO + ENS. Importantly, the ENCCs used in Schlieve's experiments were derived via a different method, as described previously by Fattahi et al.11. Briefly, hPSCs (both hESCs and hiPSCs) underwent neural crest induction in FGF2-enriched media. These cells were also treated with RA to establish an enteric vagal fate, but for 5 days (days 6-11), an increase from Workman and Mahe's 2 days (day 4-5). In 2019, Barber et al. published a revised version of the Fattahi protocol including a more thorough description of culture conditions and a transition to defined basal media to reduce inconsistency and reflect changing cell culture preferences at the time12.
Our method for innervating HIOs, described in detail below, incorporates elements of both the Workman/Mahe and Schlieve protocols. While the ENS in Schlieve's ENCC-HIO-TESI appeared more mature with greater neuronal diversity and neuroglial integration, both methods successfully integrated a functional ENS into the HIOs with demonstrated changes in gastrointestinal transcriptional expression. Workman and Mahe's HIO + ENS induced increased expression of several genes related to intestinal stem cells and epithelial cell development, which were not altered in ENCC-HIO-TESI. One possible explanation for these distinctions is the different time points when ENCCs and HIOs were combined between the protocols. Our lab has observed that early coculture results in the increased expression of multiple genes involved in epithelial and mesenchymal differentiation, and the timing of coculture influences epithelial cell diversity (unpublished data). It is possible that earlier exposure of ENS precursors to developing HIOs and vice versa provides time for yet undefined signaling crosstalk that promotes epithelial diversity and other early developmental processes.
Human embryonic stem cell (hESC) line H9 was sourced from WiCell (Madison, WI) and all experiments involving hESCs were approved by the UTHealth Houston Stem Cell Research Oversight (SCRO) Committee (protocol #SCRO-23-01). For this protocol, all references to coated plates or wells refer to those prepared with hESC-qualified 3D basement membrane matrix.
1. Cell culture preparation
NOTE: Our lab uses H9 hESCs, but multiple hPSC lines have been used successfully by other labs to generate HIOs and ENCCs, including H9 hESCs9,10,12, H1 hESCs9, hESC line UCSF412, and multiple hiPSC lines such as WTC1112, WTC11 AAVS1-CAG-GCaMP6f9, WTC109,10, WTC10 PHOX2B het (+/Y14X)9, and WTC10 PHOX2B null (Y14X/Y14X)9.
2. ENCC generation
NOTE: Our method for ENCC generation closely follows that described by the Fattahi lab and used by Schlieve et al.10. We utilize a slightly modified version of the protocol option B through the sections "Enteric Neural Crest (ENC) Induction (Days 0-12)" and "ENCC Spheroid Formation (Day 12-15)" in Barber et al.10,12.
3. HIO generation (mid-hindgut spheroid phase)
NOTE: Our method for HIO generation is fundamentally the same as the original protocol described in detail by McCracken et al. and others from the Spence and Wells labs6,7. The process occurs in two phases: Definitive endoderm (DE) induction and Mid-hindgut spheroid formation.
4. Co-culture of mid-hindgut spheroids with ENCCs
NOTE: A graphic summary of this section is provided in Figure 1.
The ENS regulates the essential functions of the mature small intestine, including peristalsis, nutrient absorption, fluid transport, and epithelial barrier maintenance. Thus, the goal of innervating HIOs is to provide these constructs with the elements needed to develop more mature, higher-level functionality. To this end, our lab specifically studies the development of the ENS within HIOs as well as the functional outcomes at different stages.
It is important to monitor cell growth, differen...
HIOs have been used as a model system for human intestinal development since the early 2010's and have become increasingly more complex since then. It is now possible to provide these constructs with an ENS, allowing for new opportunities in the study of normal development that may be applied to understanding and better treating a number of clinical gastrointestinal entities.
In vivo transplantation
ENCCs integrate into the mid-hindgut spher...
The authors do not have any conflicts of interest to disclose.
Thank you to our many collaborators and mentors, including Noah Shroyer, Michael Helmrath, James Wells, and Faranak Fattahi who have allowed us to visit their laboratories and have helped us to refine our protocol over the years. We would also like to thank Chris Mayhew and Amy Pitstick of the Pluripotent Stem Cell Facility and the Center for Stem Cell & Organoid Medicine (CuSTOM) at the Cincinnati Children's Hospital Medical Center for providing our lab with HIO training, guidance, and advice.Β This research was funded by the Texas Medical Center Digestive Diseases Center Pilot/Feasibility grant award (funded in part by NIH/NIDDK P30DK056338) (Speer), the NIDDK (NIH 1K08DK131326-01A1) (Speer), the Men of Distinction award (Speer), and the American Neurogastroenterology and Motility Society (ANMS) Transition Award (Speer).
Name | Company | Catalog Number | Comments |
100x Non-Essential Amino Acids Solution (NEAA) | ThermoFischer Scientific | 11140050 | |
15 mL conical tubes | Thermo Scientific | 12565269 | |
Accutase | STEMCELL Technologies | 07920 | "enzymatic cell detachment reagent" |
B-27 Supplement (50x), minus vitamin A | ThermoFischer Scientific | 12587010 | For ENCC |
B-27 Supplement (50x), serum free | Gibco | 17504044 | For HIO |
Bright-Line Hemacytometer | Hausser Scientific | 3120 | |
Corning Costar Ultra-Low Attachment Microplates | Fisher Scientific | 07-200-601 | |
Corning Flat-Bottom Plate 24-well, TC treated | VWR | 29442-044 | |
Corning Flat-Bottom Plate 3516 6 well | VWR | 29442-042 | |
Essential 6 Media | Thermo Fischer | A1516401 | |
Essential 8 Media | Thermo Fischer | A2858501 | Alternative stem cell media, used for ENCC plates.Β |
Fine-tip forceps | Dumont | 11223-20 | |
Forma Steri-Cycle i160 | Thermo Scientific | 50145522 | |
Gibco Advanced DMEM/F12 | ThermoFischer Scientific | 12634-010 | |
Gibco HEPES 1 M | ThermoFischer Scientific | 15630-080 | |
Gibco Neurobasal Medium | ThermoFischer Scientific | 21103-049 | |
Glutagro, 200 mM, 100x | Corning | 25-015-CI | |
Glutamax | ThermoFischer Scientific | 35050061 | |
H9 human ESC | Wicell International Stem Cell Bank | N/A | |
HyCloneTM FBS Defined | VWR | 16777-002 | |
LabGard Biological Safety Cabinet | Nuaire | Nu-430-400 | |
Matrigel GFR Basement Membrane Matrix, Phenol Red-Free, LDEV-Free | Corning | 356231 | "Clear 3D basement membrane matrix" |
Matrigel hESC-Qualified Matrix, LDEV-Free | Corning | 354277 | "3D basement membrane matrix" |
Micropipettes | Eppendorf (100-1000, 20-200, 10-100, 2-20, 0.5-10, 0.1-2.5 uL) | 2231300008 | |
mTeSR 1 | STEMCELL Technologies | 85850 | "stem cell media" Catalog number includes the 5x supplement, to be added in bulk in advance.Β |
N-2 Supplement (100x) | Gibco | 17502048 | For HIO |
N-2 Supplement, CTS (Cell Therapy Systems) | Thermo Fisher | A1370701 | For ENCC. Slightly different formulation. |
Nikon DS-Fi2 TS-100 microscope | Nikon | TS100 | |
Noggin-conditioned media | Texas Medical Center Digestive Disease Center GEMS Core, Enteroid/Organoid Sub-core | N/A | |
Penicillin-Streptomycin (10,000 U/mL) | ThermoFischer Scientific | 15140-122 | |
Recombinant Human Activin A | Cell Guidance Systems | GFH6-100 | |
Recombinant Human BMP-4 | Fisher Scientific | 314BP010 | |
Recombinant Human EGF Protein, CF | ThermoFisher Scientific | 236-EG-200 | |
Recombinant Human FGF basic/FGF2 (146 aa) Protein | ThermoFischer Scientific | 233-FB-010 | |
Recombinant Human FGF-4 | Peprotech | 100-31 | |
ReLeSR | STEMCELL Technologies | 5872 | "Stem cell dissociation reagent" |
Retinoic acid | SIGMA | R2625-50MG | |
Rnase-free Microfuge tubes, 2 mL | Thermo Scientific | AM12425 | |
RPMI 1640 Medium | ThermoFischer Scientific | 11875093 | |
R-Spondin conditioned media | Texas Medical Center Digestive Disease Center GEMS Core, Enteroid/Organoid Sub-core | N/A | |
SB 431542, Tocris Bioscience | Fisher Scientific | 16-141-0 | |
Sorvall ST 16R Centrifuge | Thermo Scientific | ||
Standard Wide Orifice Pipettor Tips | VWR | 89049-166 | |
Stemolecule Chir99021 in Solution | Stemgent | 04-0004-02 | |
Sterile filter pipette tips | VWR (1000uL, 200uL, 10uL) | 76322-154, 76322-150, 89174-520 | |
Vitronectin XF | Stem Cell Technologies | 7180 | Alternative 3D basement membrane matrix, used for ENCC plates.Β |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright Β© 2025 MyJoVE Corporation. All rights reserved